Effect of Non-Statin Lipid Lowering and Anti-Obesity Drugs on LDL Subfractions in Patients with Mixed Dyslipidaemia

Simple item page
dc.contributor.authorFlorentin, M.en
dc.contributor.authorTselepis, A. D.en
dc.contributor.authorElisaf, M. S.en
dc.contributor.authorRizos, C. V.en
dc.contributor.authorMikhailidis, D. P.en
dc.contributor.authorLiberopoulos, E. N.en
dc.date.accessioned2015-11-24T16:57:00Z
dc.date.available2015-11-24T16:57:00Z
dc.identifier.issn1570-1611-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/10520
dc.rightsDefault Licence-
dc.subjectmixed dyslipidaemiaen
dc.subjectezetimibeen
dc.subjectfibratesen
dc.subjectnicotinic aciden
dc.subjectobesityen
dc.subjectorlistaten
dc.subjectrimonabanten
dc.subjectsmallen
dc.subjectdense ldlen
dc.subjectlow-density-lipoproteinen
dc.subjectcoronary-artery-diseaseen
dc.subjecttype-2 diabetes-mellitusen
dc.subjectapolipoprotein-b metabolismen
dc.subjectischemic-heart-diseaseen
dc.subjectmicronized fenofibrateen
dc.subjectcombined hyperlipidemiaen
dc.subjectparticle-sizeen
dc.subjectobese-patientsen
dc.subjectrisk-factorsen
dc.titleEffect of Non-Statin Lipid Lowering and Anti-Obesity Drugs on LDL Subfractions in Patients with Mixed Dyslipidaemiaen
heal.abstractSmall, dense low density lipoprotein (sdLDL) particles are considered an emerging cardiovascular risk factor. Obese patients with mixed dyslipidaemia frequently have elevated sdLDL cholesterol (sdLDL-C) levels. Therefore, agents that favourably modulate the LDL phenotype may be of clinical value in these patients. We review the efficacy of anti-obesity and lipid lowering drugs other than statins on LDL subfractions in patients with mixed dyslipidaemia primarily focusing on those who are overweight/obese. The literature search was based on PubMed listings up to 26 November 2009. In most studies ezetimibe decreases the large and medium LDL subclasses and, to a lesser extent, the sdLDL particles, while it does not substantially influence LDL size. Fibrates and niacin reduce sdLDL particles and shift LDL size towards large, buoyant LDL particles. More studies are needed to elucidate the effects of fish oils and resins on LDL phenotype. Orlistat and rimonabant have been associated with reductions in sdLDL-C levels along with an increase in LDL particle size. We did not find any literature describing the effect of sibutramine on sdLDL profile. Treatment with fibrates and niacin seems to be beneficial in patients with mixed dyslipidaemia. The addition of orlistat may further improve LDL phenotype in overweight/obese patients.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.secondary<Go to ISI>://000285779100013-
heal.journalNameCurr Vasc Pharmacolen
heal.journalTypepeer reviewed-
heal.languageen-
heal.publicationDate2010-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείαςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Files

License bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.74 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά). ΧΗΜ